You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Guardian Pharmacy Services raised full-year 2026 guidance to revenue of $1.44 billion to $1.46 billion and adjusted EBITDA of $136 million to $138 million; third-quarter adjusted EBITDA increased 24% to $33.9 million.
For the nine months ended September 30, 2026, Guardian Pharmacy Services, Inc. reported net income of 54,785 and Adjusted EBITDA of 93,269, versus 27,693 and 75,659, respectively; dollar figures are in thousands.
Guardian Pharmacy Services reported third-quarter net income of $19.1 million and Adjusted EBITDA of $33.9 million, raised full-year revenue guidance to $1.44 billion -$1.46 billion and Adjusted EBITDA guidance to $136 million - $138 million.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Guardian raised its full-year 2026 guidance, with revenue now expected at $1.43–$1.45 billion and adjusted EBITDA at $129–$131 million, after Q2 adjusted EBITDA grew 19% year-over-year to $29.7 million despite a 2% reported revenue increase pressured by IRA pricing reductions.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $59.42M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA as a percentage of revenue non-GAAP | 8.6% | Six Months Ended June 30, 2026 | — |
| Adjusted EPS non-GAAP | $0.58 | Six Months Ended June 30, 2026 | — |
| Adjusted net income non-GAAP | $36.89M | Six Months Ended June 30, 2026 | — |
| Full-service pharmacies | 54 | Q2 2026 | — |
| Licensed pharmacies | 61 | Q2 2026 | — |
| Prescriptions dispensed | 7.6M | Three Months Ended June 30, 2026 filing | — |
| Residents served | 210,000 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRDN
this stock
Guardian Pharmacy Services, Inc.
|
$3.14B | +64.6% | +17.9% | — | 3.5% |
|
HCA
HCA Healthcare, Inc.
|
$104.25B | +6.9% | +7.1% | 16.6 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$33.34B | +3.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.76B | +43.9% | +0.9% | 8.3 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.83B | +32.8% | +10.5% | 22.0 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
For the nine months ended September 30, 2026, Guardian Pharmacy Services, Inc. reported net income of 54,785 and Adjusted EBITDA of 93,269, versus 27,693 and 75,659, respectively; dollar figures are in thousands.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRDN | +16.8% | +25.5% | +28.3% | +21.7% | +64.6% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +14.2% | +26.6% | +27.8% | +21.9% | +54.0% |
